Regulatory · source year
55 selected, source-linked regulatory records dated 2026. This is selective source coverage, not a complete timeline.
55 selected records.
25 connected profiles.
62 distinct public records.
Cited chronology
Exenatide
The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
Source: Federal Register via GovInfo ↗
Abaloparatide
DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Dulaglutide
DailyMed lists Structured Product Labeling version 62 for the reviewed Dulaglutide label family with a published date of 2026-08-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Tesamorelin
DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Glucagon + 5 more
The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
Source: Federal Register via GovInfo ↗
BPC-157 + 6 more
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.
Liraglutide
DailyMed lists Structured Product Labeling version 6 for the reviewed Liraglutide label family with a published date of 2026-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Glucagon
DailyMed lists Structured Product Labeling version 2 for the reviewed Glucagon label family with a published date of 2026-07-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Insulin glargine-aldy
DailyMed lists Structured Product Labeling version 5 for the reviewed Insulin glargine-aldy label family with a published date of 2026-07-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Leuprolide
DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2026-07-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 212972 with status AP dated 2026-07-01, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Exenatide
DailyMed lists Structured Product Labeling version 17 for the reviewed Exenatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Semaglutide
DailyMed lists Structured Product Labeling version 19 for the reviewed Semaglutide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Teriparatide
DailyMed lists Structured Product Labeling version 9 for the reviewed Teriparatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Liraglutide + 2 more
The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.
Source: Federal Register via GovInfo ↗
Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 213155 with status AP dated 2026-06-15, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Insulin glargine-aldy
DailyMed lists Structured Product Labeling version 2 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Insulin glargine-aldy
DailyMed lists Structured Product Labeling version 1 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Linaclotide
DailyMed lists Structured Product Labeling version 39 for the reviewed Linaclotide label family with a published date of 2026-06-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Semaglutide
DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Afamelanotide
DailyMed lists Structured Product Labeling version 11 for the reviewed Afamelanotide label family with a published date of 2026-05-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Tirzepatide
DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Glucagon + 3 more
The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.
Source: Federal Register via GovInfo ↗
Semaglutide
The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
Source: Federal Register via GovInfo ↗
Semaglutide + 2 more
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.
Insulin glargine-aldy
The official Drugs@FDA dataset lists original submission 1 for BLA 761412 with status AP dated 2026-04-29, and names insulin glargine-aldy among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Setmelanotide
The Federal Register published rule 2026-07863, attributed to FDA and its parent HHS department, on 2026-04-22. Its official title is “Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
Source: Federal Register via GovInfo ↗
BPC-157 + 6 more
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
Source: Federal Register via GovInfo ↗
Semaglutide
DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Setmelanotide
DailyMed lists Structured Product Labeling version 14 for the reviewed Setmelanotide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Retatrutide + 1 more
FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.
Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 212552 with status AP dated 2026-03-30, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Dulaglutide
DailyMed lists Structured Product Labeling version 60 for the reviewed Dulaglutide label family with a published date of 2026-03-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Lixisenatide
DailyMed lists Structured Product Labeling version 25 for the reviewed Lixisenatide label family with a published date of 2026-03-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Semaglutide
FDA announced approval of a higher-dose Wegovy product, adding a regulatory event to the semaglutide profile's selected official records.
Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 215245 with status AP dated 2026-03-11, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Exenatide
The Federal Register published notice 2026-04546, attributed to FDA and its parent HHS department, on 2026-03-09. Its official title is “Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
Source: Federal Register via GovInfo ↗
Semaglutide
DailyMed lists Structured Product Labeling version 16 for the reviewed Semaglutide label family with a published date of 2026-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Tirzepatide
DailyMed lists Structured Product Labeling version 37 for the reviewed Tirzepatide label family with a published date of 2026-03-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Octreotide + 1 more
The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide.
Source: Federal Register via GovInfo ↗
Liraglutide
DailyMed lists Structured Product Labeling version 3 for the reviewed Liraglutide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Tirzepatide
DailyMed lists Structured Product Labeling version 36 for the reviewed Tirzepatide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 217063 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 217234 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Semaglutide
DailyMed lists Structured Product Labeling version 15 for the reviewed Semaglutide label family with a published date of 2026-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Semaglutide
The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
Source: Federal Register via GovInfo ↗
Afamelanotide
DailyMed lists Structured Product Labeling version 10 for the reviewed Afamelanotide label family with a published date of 2026-02-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Tirzepatide
DailyMed lists Structured Product Labeling version 32 for the reviewed Tirzepatide label family with a published date of 2026-02-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Octreotide
DailyMed lists Structured Product Labeling version 2 for the reviewed Octreotide label family with a published date of 2026-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Tirzepatide
DailyMed lists Structured Product Labeling version 31 for the reviewed Tirzepatide label family with a published date of 2026-01-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Linaclotide
DailyMed lists Structured Product Labeling version 38 for the reviewed Linaclotide label family with a published date of 2026-01-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 217590 with status AP dated 2026-01-14, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Exenatide
DailyMed lists Structured Product Labeling version 16 for the reviewed Exenatide label family with a published date of 2026-01-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Semaglutide
DailyMed lists Structured Product Labeling version 14 for the reviewed Semaglutide label family with a published date of 2026-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Tesamorelin
DailyMed lists Structured Product Labeling version 8 for the reviewed Tesamorelin label family with a published date of 2026-01-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.